PTSD trials suggest ecstasy could also be a treatment for depression

Increasing consideration is being given to 3,4-Methylene-dioxymethamphetamine (MDMA or “ecstasy”) as a possible treatment approach for depression.

In a review of current literature published in Therapeutic Advances in Psychopharmacology, authors Rachel Patel of Green Templeton College and Daniel Titheradge of St Hugh’s College discuss the pros and cons of treating depression with MDMA, noting that clinical trials already in place examining the utility of treating PTSD with MDMA have contributed to an interest in examining how MDMA may be used to treat depression.